I agree ..... the stock price is ridiculous at these prices. If one actually models the potential license value of a bovine candidate in the global market alone .... the possibility is quite large and the risk/reward sizable.
But I'm really thinking canine might be in play first. Dunno who is interested in this as a partner ..... but clearly HEPI is following a similar path as bovine as it relates to proving this out. Dahl has put it out there that the detailed testing they are doing is typically a requirement of these major companies in order to get involved. That is clearly evidenced by the testing requirements requested by Zoetis as part of that collaboration.
U Wisc for bovine and Dairy Experts. U Miss for canine and Charles River.
Experts in their respective fields.
But the canine doesn't yet have any attachment to a potential partner so I think testing results against glucosamine will be very interesting to see combined with Charles River data. A positive compare with the added immune benefits ought to catch some attention. If I were HEPI I'd be sharing those results with every major with a canine division and supplement/ingredient manufacturers for both animal and human possibilities. Grab a partner for human development too ...... glucosamine market is big and a tiny piece of it is also quite large.
News 
Market Data 
Discover 
